4
Changes in Ownership
GYRE THERAPEUTICS, INC. Filed Acc 0001140361-26-024449
Chief Operating Officer sold 34,976 shares at an average $6.25 ($218,561)
- Chief Operating Officer acquired 34,976 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ye Weiguo Chief Operating Officer | 2026-06-04 | Option exercise | +19,575 | $0.75 | $14,681 | 719,575 | D: show line 1 in the form |
| Ye Weiguo Chief Operating Officer | 2026-06-04 | Sale | −19,575 | $6.13 | $119,995 | 700,000 | D: show line 2 in the form |
| Ye Weiguo Chief Operating Officer | 2026-06-05 | Option exercise | +15,401 | $0.75 | $11,551 | 715,401 | D: show line 3 in the form |
| Ye Weiguo Chief Operating Officer | 2026-06-05 | Sale | −15,401 | $6.40 | $98,566 | 700,000 | D: show line 4 in the form |
| Open-market sales · 34,976 sh · avg $6.25 · $218,561 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Ye Weiguo Chief Operating Officer | 2026-06-04 | Option exercise · Stock Option (Right to Buy) | −19,575 | 877,820 | D: show line 5 in the form | |||||
| Ye Weiguo Chief Operating Officer | 2026-06-05 | Option exercise · Stock Option (Right to Buy) | −15,401 | 862,419 | D: show line 6 in the form |
Loading xslF345X06/form4.xml…